Modes of resistance to anti-angiogenic therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Vascular endothelial growth factor (VEGF) signaling pathway inhibitors demonstrate therapeutic efficacy in preclinical cancer models and human cancers.
• Therapeutic benefits of VEGF inhibitors are often transient, leading to tumor growth and progression due to resistance mechanisms.
• Understanding resistance is crucial for developing enduring anti-angiogenic therapies.

Purpose of the Study:

• To investigate the underlying mechanisms of resistance to anti-angiogenic therapies targeting VEGF.
• To differentiate between evasive and intrinsic resistance to VEGF inhibitors.
• To inform the design of novel pharmacological strategies for sustained anti-angiogenic treatment.

Main Methods:

• Analysis of preclinical cancer models and clinical data from patients treated with VEGF inhibitors.
• Investigation of molecular mechanisms driving tumor adaptation and resistance.
• Comparative assessment of evasive and intrinsic resistance patterns across different tumor types.

Main Results:

• VEGF inhibitors provide temporary efficacy, followed by tumor regrowth.
• Two primary resistance modes identified: evasive resistance (circumventing blockade) and intrinsic resistance (pre-existing indifference).
• Multiple mechanisms contribute to both resistance types, varying by tumor context.

Conclusions:

• Resistance to VEGF inhibitors is a significant limitation in cancer therapy.
• Distinguishing between evasive and intrinsic resistance is key to overcoming treatment limitations.
• Further research into resistance mechanisms will guide the development of more effective and durable anti-angiogenic drugs.